Dr Jong W Kim, MD in Bladenboro, NC - Internal Medicine

Dr Jong W Kim, MD is a Internal Medicine - Geriatric Medicine physician based in Bladenboro, North Carolina. Dr Jong W Kim is licensed to practice in North Carolina (license number 200101455) and his current practice location is 8100 Twisted Hickory Rd, Bladenboro, North Carolina. He can be reached at his office (for appointments etc.) via phone at (910) 862-5500.

NPI number for Dr Jong W Kim is 1740379981 and his current mailing address is 8100 Twisted Hickory Rd, Bladenboro, North Carolina. He does not participate in medicare program and thus does not accept medicare assignments. His NPI Number is 1740379981.

Contact Information

	Dr Jong W Kim, MD
	8100 Twisted Hickory Rd, Bladenboro, NC 28320-7010
	(910) 862-5500
	(910) 862-2107

Physician's Profile

Full Name	Dr Jong W Kim
Gender	Male
Speciality	Internal Medicine - Geriatric Medicine
Location	8100 Twisted Hickory Rd, Bladenboro, North Carolina
Accepts Medicare Assignments	Does not participate in Medicare Program. He may not accept medicare assignment.

NPI Data:

NPI Number: 1740379981
Provider Enumeration Date: 10/12/2006
Last Update Date: 09/20/2017

Medical Identifiers

Medical identifiers for Dr Jong W Kim such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1740379981	NPI	-	NPPES

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
207RG0300X	Internal Medicine - Geriatric Medicine	200101455 (North Carolina)	Primary

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Dr Jong W Kim is NOT enrolled with medicare and thus cannot prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Dr Jong W Kim, MD 8100 Twisted Hickory Rd, Bladenboro, NC 28320-7010 Ph: (910) 876-7301	Dr Jong W Kim, MD 8100 Twisted Hickory Rd, Bladenboro, NC 28320-7010 Ph: (910) 862-5500

News Archive

Silence Therapeutics, AstraZeneca announce one-year extension of ongoing siRNA delivery collaboration

Silence Therapeutics plc announces that the Company and AstraZeneca have agreed to a one-year extension of their ongoing small interfering RNA (siRNA) delivery collaboration. Under this collaboration, which was originally entered into in March 2008, the companies are leveraging a number of Silence's proprietary lipid delivery and targeting technologies to develop new and enhanced delivery approaches for RNA interference (RNAi) therapeutics.

Researchers discover novel genes responsible for Alzheimer's disease

Researchers have identified several new genes responsible for Alzheimer's disease (AD) including those leading to functional and structural changes in the brain and elevated levels of AD proteins in cerebrospinal fluid (CSF).

Hypertension drug market to decrease through 2013 due to generic erosion and few emerging therapies

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, in addition to extensive generic erosion, the hypertension drug market will be constrained through 2018 by a pipeline containing very few emerging therapies with novel mechanisms of action. Gilead's darusentan was positioned to be the next emerging therapy with a novel mechanism of action to reach the hypertension market. However, following darusentan's failure to meet its primary endpoint in the recent DORADO-AC Phase III clinical trial, further development of the agent has been terminated.

Majority of parents want schools to limit students' access to high-calorie foods

The vast majority of parents want schools to limit students' access to high-calorie chips, sodas and candy and to offer them opportunities for physical activity throughout the day, a new survey by the Alliance for a Healthier Generation shows.

UL Environment experts to serve as advisory board member of Johns Hopkins Center for Alternatives to Animal Testing

UL (Underwriters Laboratories), a global safety science leader, announced today that UL Environment's Craig Rowlands, PhD, DABT, senior toxicologist, will serve as an advisory board member of Johns Hopkins Center for Alternatives to Animal Testing (CAAT) and UL Environment's Anne Bonhoff, PhD, global head of chemistry, will serve as an advisory board member of the European branch (CAAT-Europe) located at the University of Konstanz, Germany.

Dr Jong W Kim, MD - Internal Medicine in Bladenboro, NC